R&D Alzheimer’s: Starting the impossible journey September was Alzheimer’s Month, and with that in mind pharmaphorum spoke to leaders at two biotechs about latest developments in the field.
News Scenic Bio raises $31m for genetic modifier platform 18 months after signing its first partnering deal with Genentech, Scenic Biotech has raised $31 million in first-round financing that it will use to take its own genetic modifier-targeted m
News AZ grabs FDA nod for Ultomiris in rare kidney disease IgAN AstraZeneca has staked a claim to the increasingly crowded IgAN market with an accelerated approval from the FDA for Ultomiris, its fifth indication.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.